 | | Vol. 15.34 – 31 August, 2023 |
| |
|
|
| Researchers showed that MYC activation drove resistance to mTOR inhibitors in breast cancer. MYC status was significantly associated with poor response to everolimus therapy in metastatic breast cancer patients.
[Journal of Experimental Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The expressions and clinicopathological characteristics of SAM pointed domain containing ETS transcription factor (SPDEF) in luminal breast cancer patients were evaluated bioinformatically.
[Cell Death & Disease] |
|
|
|
| The authors investigated the clinical implications and underlying mechanisms of circ_0042881 in breast cancer (BC). Functionally, circ_0042881 significantly accelerated the proliferation, migration, and invasion of BC cells in vitro and tumor growth and metastasis in vivo.
[Cell Death & Disease] |
|
|
|
| Investigators reported on a novel nanotechnology-based approach to target tumor-associated immune cells and promoted “anti-tumor” responses in a murine model of breast cancer.
[Biomaterials Science] |
|
|
|
| Scientists reported that Nutrient Autophagy Factor 1 was efficient in killing BT-549, Hs 578T, MDA-MB-436, and MDA-MB-453 breast cancer cells, but that MDA-MB-157 cells were resistant to it.
[Cell Death Discovery] |
|
|
|
| The authors found that DEPDC1B was highly expressed in breast cancer cells and tissues and was associated with lower overall survival in patients.
[American Journal Of Physiology-Cell Physiology] |
|
|
|
| Researchers found that the exp-cancer-associated fibroblasts highly expressed Runt-related transcription factor 3 (RUNX3), while counterpart fibroblasts did not.
[Cancer Medicine] |
|
|
|
| Scientists compared the effect of 2-methoxyestradiol in early- and late-stage breast cancer using a transgenic mouse model—FVB/N-Tg—of spontaneously development of aggressive mammary carcinoma with lung metastasis.
[Cell Biochemistry and Function] |
|
|
|
| A non-toxic concentration of folate-conjugated palladium-based nanoparticles was used to target the overexpressed folate receptor in breast cancer cells.
[Nanotechnology] |
|
|
|
|
|
The authors investigate the possible role of the metabolic/hypoxial axis LncRNA taurine up-regulated 1, miR-186, sirtuin-3, peroxisome proliferator activator receptor alpha, and hypoxia-inducible factor-1 in the development of tamoxifen resistance in breast cancer patients.
[Human Cell] |
| |
|
|
| Nicholas Harper, a PhD candidate at UMass Chan Medical School, has received a prestigious Ruth L. Kirschstein National Research Service Award Individual Predoctoral Fellowship from the National Cancer Institute to study cell death as it relates to cancer therapies.
[UMass Chan Medical School] |
|
|
|
|
| October 16 – 19, 2023
Hong Kong |
|
|
|
|
|
| | University of Cologne – Cologne, Germany |
|
|
|
| | Cedars-Sinai – Los Angeles, California, United States |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | Cedars-Sinai – Los Angeles, California, United States |
|
|
|
| | Creative Biolabs – New York, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
